CLSD Clearside Biomedical Quarterly Revenue Growth

Corporate company logo of Clearside Biomedical, Inc. (CLSD)

Clearside Biomedical generates revenue by licensing unique drug delivery methods for the posterior segment of the eye. This quarterly revenue chart, where the current level is -80.80, reflects the dynamics of financial flows. Growth is supported by targeted partnerships with research centers. The foundation of this success is the SCS microinjector, which ensures precise drug administration into the suprachoroidal space to minimize side effects.

CLSD Clearside Quarterly Revenue Increase (07/04/2022 - 12/13/2025)

Metric breakdowns and analytics for Clearside Biomedical, Inc. (CLSD)

Fundamental valuation:Clearside Biomedical Inc (CLSD)
Manufactured products of clearsidebio.com

This indicator calculates the percentage change in current quarter revenue relative to the same period last year, determining the business scaling rates and its market resilience. For Clearside Biomedical (CLSD), the quarterly sales growth value reflects the company's ability to monetize ophthalmological developments amid geopolitical risks and potential supply chain disruptions of critical imported raw materials.